Mostrar o rexistro simple do ítem

dc.contributor.authorPeral, Carmen
dc.contributor.authorCordido, Fernando
dc.contributor.authorGimeno-Ballester, Vicente
dc.contributor.authorMir, Nuria
dc.contributor.authorSánchez-Cenizo, Laura
dc.contributor.authorRubio-Rodríguez, Darío
dc.contributor.authorRubio-Terrés, Carlos
dc.date.accessioned2020-05-08T11:35:14Z
dc.date.available2020-05-08T11:35:14Z
dc.date.issued2020-05-06
dc.identifier.citationPeral C, Cordido F, Gimeno-Ballester V, Mir N, Sánchez-Cenizo L, Rubio-Rodríguez D, Rubio-Terrés C. Cost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spain. Expert Rev Pharmacoecon Outcomes Res. 2020 Feb;20(1):105-114.es_ES
dc.identifier.issn1744-8379
dc.identifier.urihttp://hdl.handle.net/2183/25526
dc.description.abstract[Abstract] Objective: To estimate the cost-effectiveness of second-line pharmacological treatments in patients with acromegaly resistant to first-generation somatostatin analogues (FG SSA) from the Spanish National Health System (NHS) perspective. Methods: A Markov model was developed to analyze the cost-effectiveness of pegvisomant and pasireotide in FG SSA-resistant acromegaly, simulating a cohort of patients from the treatment beginning to death. Treatment with pegvisomant or pasireotide was compared to FG SSA retreatment. Efficacy data were obtained from clinical trials and utilities from the literature. Direct health costs were obtained from Spanish sources (€2018). Results: The Incremental Cost Effectiveness Ratio (ICER) of pegvisomant vs. FG SSA was €85,869/ Quality-adjusted life years (QALY). The ICER of pasireotide vs. FG SSA was €551,405/QALY. The ICER was mainly driven by the incremental efficacy (4.41 QALY for pegvisomant vs. FG SSA and 0.71 QALY for pasireotide vs. FG SSA), with a slightly lower increase in costs with pegvisomant (€378,597 vs. FG SSA) than with pasireotide (€393,151 vs. FG SSA). Conclusion: The ICER of pasireotide compared to FG SSA was six times higher than the ICER of pegvisomant vs. FG SSA. Pegvisomant is a more cost-effective alternative for the treatment of acromegaly in FG SSA-resistant patients in the Spanish NHS.es_ES
dc.language.isoenges_ES
dc.publisherTaylor&Francises_ES
dc.relation.urihttps://doi.org/10.1080/14737167.2019.1610396es_ES
dc.rightsCreative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC-BY-NC-ND 4.0)es_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAcromegalyes_ES
dc.subjectCost-effectivenesses_ES
dc.subjectPasireotidees_ES
dc.subjectPegvisomantes_ES
dc.subjectSomatostatin analogueses_ES
dc.titleCost-effectiveness analysis of second-line pharmacological treatment of acromegaly in Spaines_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessinfo:eu-repo/semantics/openAccesses_ES
UDC.journalTitleExpert Review of Pharmacoeconomics & Outcomes Researches_ES
UDC.volume20es_ES
UDC.issue1es_ES
UDC.startPage105es_ES
UDC.endPage114es_ES


Ficheiros no ítem

Thumbnail
Thumbnail
Thumbnail

Este ítem aparece na(s) seguinte(s) colección(s)

Mostrar o rexistro simple do ítem